oral semaglutide phase 3 Study reveals 50 mg as promising treatment for obesity in adults: the Lancet report The evoke and evoke+ phase

Weight loss may begin, though the scale reflects both water loss and fat reduction

A weekly injection protocol designed to target multiple components blood sugar, cravings, satiety that can provide significant, sustained weight loss

www.tga.gov.au

Check the pen label and liquid, attach a sterile needle, set the prescribed dose, and choose an approved injection site

(2024) 16:e71684

Participants with type 2 diabetes experienced an average weight reduction of 16.9% over the 8-month study period, which is considered the most substantial weight loss reported so far for a medication tested in type 2 diabetes treatment [R]